Top

International Journal of Colorectal Disease

Published in:

01-06-2021 | Rectal Cancer | Original Article

Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer

Authors: Seung Ho Song, Jun Seok Park, Min Kyu Kang, Gyu-Seog Choi, Soo Yeun Park, Hye Jin Kim, Jong Gwang Kim, Byung Woog Kang, Jin Ho Baek, Dong Won Baek, Jae-Chul Kim, Shin-Hyung Park, Seung Hyun Cho, An Na Seo

Published in: International Journal of Colorectal Disease | Issue 6/2021

Abstract

Purpose

We analyzed the safety and feasibility of preoperative short-course radiotherapy (SCRT) followed by consolidation chemotherapy for patients with locally advanced rectal cancer (LARC).

Methods

From April 2018 to May 2019, 19 patients with LARC were treated with SCRT followed by three cycles of consolidation chemotherapy with leucovorin, fluorouracil, and oxaliplatin (FOLFOX6) before surgery. Adjuvant chemotherapy relied on oxaliplatin. Tumor response, patient compliance, and toxicities were analyzed.

Results

The median age was 60 years (range 44–71), and 16 of the patients were male. The median tumor height was 5 cm (range 0–9) from anal verge. All patients received a total dose of 25 Gy in five fractions. The number of cycles of FOLFOX6 before surgery was three in 17, four in one, five in one. Five patients required dose reductions in consolidation chemotherapy. The median interval between initiation of SCRT and surgery was 10.6 weeks (range 8.6–16.4). A pathologic complete response was seen in two patients (11%). Grade III toxicities to the preoperative treatment were seen in five patients (26%): diarrhea in two, a decreased white blood cell count in one, and anemia in two. Postoperative complications arising within 30 days developed in five patients (26%). During the median follow-up period of 20.4 months, there was no tumor recurrence.

Conclusion

Preoperative SCRT followed by oxaliplatin-based consolidation chemotherapy showed acceptable toxicity and feasibility in patients with LARC. Prospective randomized trials are warranted to verify the efficacy and safety of this treatment strategy compared with conventional long-course concurrent chemoradiotherapy.

Available only for authorised users

Maehara Y, Soejima Y, Yoshizumi T, Kawahara N, Oki E, Saeki H, Akahoshi T, Ikegami T, Yamashita YI, Furuyama T, Sugimachi K, Harada N, Tagawa T, Harimoto N, Itoh S, Sonoda H, Ando K, Nakashima Y, Nagao Y, Yamashita N, Kasagi Y, Yukaya T, Kurihara T, Tsutsumi R, Takamori S, Sasaki S, Ikeda T, Yonemitsu Y, Fukuhara T, Kitao H, Iimori M, Kataoka Y, Wakasa T, Suzuki M, Teraishi K, Yoshida Y, Mori M (2019) The evolution of surgical treatment for gastrointestinal cancers. Int J Clin Oncol 24(11):1333–1349. https://doi.org/10.1007/s10147-019-01499-7CrossRefPubMed

Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373(9666):811–820. https://doi.org/10.1016/S0140-6736(09)60484-0CrossRefPubMedPubMedCentral

van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius B, van de Velde CJ, Dutch Colorectal Cancer Group (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12(6):575–582. https://doi.org/10.1016/S1470-2045(11)70097-3CrossRefPubMed

Kim JH (2017) Controversial issues in radiotherapy for rectal cancer: a systematic review. Radiat Oncol J 35(4):295–305. https://doi.org/10.3857/roj.2017.00395CrossRefPubMedPubMedCentral

Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740. https://doi.org/10.1056/NEJMoa040694CrossRefPubMed

Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan SA, McKendrick J, Leong T, Hartopeanu C, Zalcberg J, Mackay J (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30(31):3827–3833. https://doi.org/10.1200/JCO.2012.42.9597CrossRefPubMed

Ciseł B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, Cencelewicz A, Spałek M, Polkowski W, Jankiewicz M, Styliński R, Bębenek M, Kapturkiewicz B, Maciejczyk A, Sadowski J, Zygulska J, Zegarski W, Jankowski M, Las-Jankowska M, Toczko Z et al (2019) Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol 30(8):1298–1303. https://doi.org/10.1093/annonc/mdz186CrossRefPubMed

Park JS, Park SY, Kim HJ, Cho SH, Kwak SG, Choi GS (2019) Long-term oncologic outcomes after neoadjuvant chemoradiation followed by intersphincteric resection with coloanal anastomosis for locally advanced low rectal cancer. Dis Colon Rectum 62(4):408–416. https://doi.org/10.1097/DCR.0000000000001321CrossRefPubMed

Kim HJ, Choi GS, Park JS, Park SY, Lee HJ, Woo IT, Park IK (2018) Selective lateral pelvic lymph node dissection: a comparative study of the robotic versus laparoscopic approach. Surg Endosc 32(5):2466–2473. https://doi.org/10.1007/s00464-017-5948-4CrossRefPubMed

10.

Siddiqui MRS, Simillis C, Hunter C, Chand M, Bhoday J, Garant A, Vuong T, Artho G, Rasheed S, Tekkis P, Abulafi AM, Brown G (2017) A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases. Br J Cancer 116(12):1513–1519. https://doi.org/10.1038/bjc.2017.99CrossRefPubMedPubMedCentral

11.

Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT (2003) Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 90(3):355–364. https://doi.org/10.1002/bjs.4034CrossRefPubMed

12.

Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, Quirke P, Sebag-Montefiore D, Moran B, Heald R, Guthrie A, Bees N, Swift I, Pennert K, Brown G (2011) Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 29(28):3753–3760. https://doi.org/10.1200/JCO.2011.34.9068CrossRefPubMed

13.

Edge SB, Byrd DR, Compton CC (2011) AJCCCancer Staging Handbook in the AJCCCancer Staging Manual, 7th edn. Springer, New York

14.

Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23(34):8688–8696. https://doi.org/10.1200/JCO.2005.02.1329CrossRefPubMed

15.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213. https://doi.org/10.1097/01.sla.0000133083.54934.aeCrossRefPubMedPubMedCentral

16.

Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Schmiegel W, Jacobasch L, Weitz J, Folprecht G, Schlenska-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V et al (2019) Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol 37(34):3212–3222. https://doi.org/10.1200/JCO.19.00308CrossRefPubMed

17.

van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes AMR, de Groot DJA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP, Collaborative investigators (2020) Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - results of the international randomized RAPIDO-trial. Radiother Oncol 147:75–83. https://doi.org/10.1016/j.radonc.2020.03.011CrossRefPubMed

18.

Bahadoer RR, Dijkstra EA, van Etten B, Marijnen C, Putter H, Kranenbarg EM, Roodvoets A, Nagtegaal ID, Beets-Tan R, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde C, Hospers G et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22(1):29–42. https://doi.org/10.1016/S1470-2045(20)30555-6CrossRefPubMed

19.

Battersby NJ, Dattani M, Rao S, Cunningham D, Tait D, Adams R, Moran BJ, Khakoo S, Tekkis P, Rasheed S, Mirnezami A, Quirke P, West NP, Nagtegaal I, Chong I, Sadanandam A, Valeri N, Thomas K, Frost M, Brown G (2017) A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials 18(1):394. https://doi.org/10.1186/s13063-017-2085-2CrossRefPubMedPubMedCentral

20.

Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB (2014) Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 32(6):513–518. https://doi.org/10.1200/JCO.2013.51.7904CrossRefPubMedPubMedCentral

21.

Kim CW, Kang BM, Kim IY, Kim JY, Park SJ, Park WC, Bae KB, Bae BN, Baek SK, Baik SH, Son GM, Lee YS, Lee SH (2018) Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE). BMC Cancer 18(1):538. https://doi.org/10.1186/s12885-018-4466-7CrossRefPubMedPubMedCentral

22.

Park IJ, Choi GS, Lim KH, Kang BM, Jun SH (2009) Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol 16(11):3087–3093. https://doi.org/10.1245/s10434-009-0625-zCrossRefPubMed

23.

Chapman MA, Buckley D, Henson DB, Armitage NC (1998) Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer 78(10):1346–1349. https://doi.org/10.1038/bjc.1998.682CrossRefPubMedPubMedCentral

24.

Chand M, Siddiqui MR, Swift I, Brown G (2016) Systematic review of prognostic importance of extramural venous invasion in rectal cancer. World J Gastroenterol 22(4):1721–1726. https://doi.org/10.3748/wjg.v22.i4.1721CrossRefPubMedPubMedCentral

25.

Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, Meunier B, Mehrdad J, Cotte E, Desrame J, Karoui M, Benoist S, Kirzin S, Berger A, Panis Y, Piessen G, Saudemont A, Prudhomme M, Peschaud F, Dubois A, Loriau J, Tuech JJ, Meurette G, Lupinacci R, Goasgen N, Parc Y, Simon T, Tiret E (2016) Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 34(31):3773–3780. https://doi.org/10.1200/JCO.2016.67.6049CrossRefPubMed

26.

Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, Kumar AS, Oommen S, Coutsoftides T, Hunt SR, Stamos MJ, Ternent CA, Herzig DO, Fichera A, Polite BN, Dietz DW, Patil S, Avila K, Timing of Rectal Cancer Response to Chemoradiation Consortium (2015) Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 16(8):957–966. https://doi.org/10.1016/S1470-2045(15)00004-2CrossRefPubMedPubMedCentral

27.

Ansari N, Solomon MJ, Fisher RJ, Mackay J, Burmeister B, Ackland S, Heriot A, Joseph D, McLachlan SA, McClure B, Ngan SY (2017) Acute adverse events and postoperative complications in a randomized trial of preoperative short-course radiotherapy versus long-course chemoradiotherapy for T3 adenocarcinoma of the rectum: trans-tasman radiation oncology group trial (TROG 01.04). Ann Surg 265(5):882–888. https://doi.org/10.1097/SLA.0000000000001987CrossRefPubMed

28.

Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27(31):5124–5130. https://doi.org/10.1200/JCO.2009.22.0467CrossRefPubMedPubMedCentral

29.

Erlandsson J, Holm T, Pettersson D, Berglund Å, Cedermark B, Radu C, Johansson H, Machado M, Hjern F, Hallböök O, Syk I, Glimelius B, Martling A (2017) Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 18(3):336–346. https://doi.org/10.1016/S1470-2045(17)30086-4CrossRefPubMed

30.

Koëter T, van Elderen SGC, van Tilborg GFAJB, de Wilt JHW, Wasowicz DK, Rozema T, Zimmerman DDE (2020) MRI response rate after short-course radiotherapy on rectal cancer in the elderly comorbid patient: results from a retrospective cohort study. Radiat Oncol 15(1):53. https://doi.org/10.1186/s13014-020-01500-yCrossRefPubMedPubMedCentral

31.

Sclafani F, Brown G, Cunningham D, Wotherspoon A, Mendes LST, Balyasnikova S, Evans J, Peckitt C, Begum R, Tait D, Tabernero J, Glimelius B, Roselló S, Thomas J, Oates J, Chau I (2017) Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. Br J Cancer 117(10):1478–1485. https://doi.org/10.1038/bjc.2017.320CrossRefPubMedPubMedCentral

Title: Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer
Authors: Seung Ho Song
Jun Seok Park
Min Kyu Kang
Gyu-Seog Choi
Soo Yeun Park
Hye Jin Kim
Jong Gwang Kim
Byung Woog Kang
Jin Ho Baek
Dong Won Baek
Jae-Chul Kim
Shin-Hyung Park
Seung Hyun Cho
An Na Seo
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keywords: Rectal Cancer
Rectal Cancer
Radiotherapy
Cytostatic Therapy
Published in: International Journal of Colorectal Disease / Issue 6/2021
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-021-03875-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2021

Use of a standardized discharge checklist with daily post-operative C-reactive protein monitoring does not impact readmission rates after colon and rectal surgery

The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease

Effective dissection for rectal cancer with lateral lymph node metastasis based on prognostic factors and recurrence type

Risk factors affecting failure of colonoscopic detorsion for sigmoid colon volvulus: a single center experience

Defining early recurrence in patients with resected primary colorectal carcinoma and its respective risk factors

C-reactive protein can predict anastomotic leak in colorectal surgery: a systematic review and meta-analysis